Results 111 to 120 of about 1,829 (202)

Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival

Brain Pathology, EarlyView.
Untargeted multiomic profiling of cerebrospinal fluid reveals that proteomic, but not lipidomic, signatures robustly distinguish ALS patients from controls and stratify individuals by survival, highlighting marked molecular differences between short survival and long survival disease.
Sergio Roca‐Pereira, Yaiza López‐Sampere, Pol Mengod‐Soler, Mario Peña‐Fonteboa, Carla Marco, Alejandro Caravaca‐Puchades, Raúl Domínguez, Juan Francisco Vázquez‐Costa, Enrique Santamaría, Joaquín Fernández‐Irigoyen, María J. Colomina, Isabel León Moreno, Antonio Martínez Yélamos, Sergio Martínez Yélamos, Gabriel Santpere, Elia Obis, Manuel Portero‐Otín, Gerard Piñol‐Ripoll, Mónica Povedano, Pol Andrés‐Benito   +19 more
wiley   +1 more source

The acidic intrinsically disordered region of the inflammatory mediator HMGB1 mediates fuzzy interactions with CXCL12

Nature Communications
Chemokine heterodimers activate or dampen their cognate receptors during inflammation. The CXCL12 chemokine forms with the fully reduced (fr) alarmin HMGB1 a physiologically relevant heterocomplex (frHMGB1•CXCL12) that synergically promotes the ...
Malisa Vittoria Mantonico, Federica De Leo, Giacomo Quilici, Liam Sean Colley, Francesco De Marchis, Massimo Crippa, Rosanna Mezzapelle, Tim Schulte, Chiara Zucchelli, Chiara Pastorello, Camilla Carmeno, Francesca Caprioglio, Stefano Ricagno, Gabriele Giachin, Michela Ghitti, Marco Emilio Bianchi, Giovanna Musco   +16 more
doaj   +1 more source

Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐TAIL‐2

Cancer Science, EarlyView.
BLURB FOR ETOC: The J‐TAIL‐2 study (NCT04501497) evaluated the efficacy and safety of atezolizumab, an anti‐programmed death‐ligand 1, plus chemotherapy in patients with non‐small cell lung cancer (NSCLC) and extensive‐stage small cell lung cancer (ES‐SCLC) in real‐world settings.
Yasushi Goto, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Junichi Shimizu, Eisaku Miyauchi, Hiroshige Yoshioka, Ichiro Yoshino, Toshihiro Misumi, Yasutaka Watanabe, Nobuyuki Katakami, Akira Kisohara, Masafumi Yamaguchi, Hirotaka Kuroki, Masamichi Sugimoto, Hisao Ashimura, Misa Tanaka, Akihiko Gemma   +19 more
wiley   +1 more source

Involvement of CXCL12/CXCR4 in CB2 receptor agonist-attenuated morphine tolerance in Walker 256 tumor-bearing rats with cancer pain

European Journal of Medical Research
While low-dose cannabinoid 2 (CB2) receptor agonists attenuate morphine tolerance in cancer pain models, chemokine ligand 12 (CXCL12)/chemokine receptor 4 (CXCR4) expression induces morphine tolerance.
Dandan Liu, Mingyue Zhang, Xiaohai Xu, Xuelai Zhong, Chao Ma, Xiaoyu Zheng, Xiaohong Wu, Guonian Wang   +7 more
doaj   +1 more source

Super‐Enhancer Formation in Scirrhous Gastric CAFs, and the Presence of a Stromal Field in Non‐Cancerous Tissues

Cancer Science, EarlyView.
While CAFs are produced as a result of education by cancer cells in non‐scirrhous gastric cancer, normal fibroblasts of scirrhous gastric cancer patients are already pre‐conditioned, forming a stromal field for scirrhous gastric cancer. ABSTRACT Scirrhous gastric cancer has aggressive clinical courses and is characterized by dominating cancer ...
Yoshimi Yasukawa, Naoko Hattori, Yu‐Yu Liu, Masayuki Tobo, Genki Yamagishi, Takahiro Irie, Shigeki Sekine, Tohru Kiyono, Satoshi Yamashita, Yukinori Yamagata, Takaki Yoshikawa, Yasuyuki Seto, Toshikazu Ushijima   +12 more
wiley   +1 more source

CXCL12-targeting siRNA nanoparticles alleviate immunosuppression and inhibit tumor progression in esophageal squamous cell carcinoma

Journal of Nanobiotechnology
Esophageal squamous cell carcinoma (ESCC) is associated with a highly immunosuppressive tumor microenvironment (TME), driven in part by cancer-associated fibroblasts (CAFs) that promote immune evasion through the secretion of CXCL12.
Shuyao Zhang, Hong Jiang, Chengkuan Zhao, Yanli Lei, Shaojie Liu, Chengcheng Xu, Xiaoshan Chen, Danling Zheng, Xiaolong Wu, Xinyue Lin, Wang Chen, Yun Chen, Jianxiang Huang, XiaoLong Wei, Yihui Huang, Chaoxian Lin   +15 more
doaj   +1 more source

CXCL12 wt Allele [PDF]

, 2020
openaire   +1 more source

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

European Journal of Haematology, EarlyView.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Mamdouh Skafi, Valter Gattei, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source

A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer

The FEBS Journal, EarlyView.
Matrix metalloproteinases (MMPs) orchestrate cancer progression and metastasis through proteolytic and non‐proteolytic actions. By remodeling the tumor microenvironment, enhancing growth factor availability, and modulating cell behavior, MMPs promote proliferation, migration or invasion, and epithelial‐to‐mesenchymal transition. Alongside extracellular
Zoi Piperigkou, Sylvia Mangani, Spyros Kremmydas, Nikolaos E. Koletsis, Nikos K. Karamanos   +4 more
wiley   +1 more source